Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.
Search results for: Tofacitinib
An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report
According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.
Insights into JAK Inhibitor Use
According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.
Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session
Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.
Cardiovascular Risks & Insights from ACR Convergence 2021
Experts share insights into how LDL & HDL levels are affected by inflammation & the treatment of rheumatic disease, addressing how targeting these levels may improve cardiovascular outcomes for patients.
Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…
Update on Extrapulmonary Sarcoidosis
Neurosarcoidosis & sarcoid dermatopathology are discussed.
Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed
Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.
From Strength to Strength: Idiopathic Inflammatory Myopathy Diagnosis & Management
During the ACR Convergence 2021 Review Course, Rohit Aggarwal, MD, MS, provided an update on idiopathic inflammatory myopathy.
FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting
ACR Convergence 2021—The recent Boxed Warning requirement applied to three Janus kinase (JAK) inhibitors, cautioning doctors and patients about several major risks in patients with rheumatoid arthritis, came only after rigorous data collection and careful consideration of the risks and the benefits, U.S. Food & Drug Administration (FDA) officials said in November at ACR Convergence…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 19
- Next Page »